^
Association details:
| Biomarker: | LAG3 overexpression |
|---|---|
| Cancer: | Melanoma |
| Drug Class: | PD1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients
Published date:
05/07/2021
Excerpt:
CONTRADICTING EVIDENCE:...resistance to antiPD1 treatment (n=48) was associated with high pre-treatment serum levels of sLAG3 (DCR: p=0.009; PFS: p=0.018; ROC cut-off > 148 pg/ml)…soluble immune checkpoints characterized checkpoint inhibitor-resistant melanoma.
Source:
Title:
Transcriptomic and immunophenotypic profiles of melanoma tissue from patients (pts) treated with anti-PD-1 +/- ipilimumab to define mechanisms of response and resistance.
Published date:
05/16/2018
Excerpt:
141 melanoma biopsies from advanced melanoma pts treated with anti-PD-1 monotherapy (n= 54), or anti-PD1 + ipilimumab (n= 51) were classified as responders (CR/PR/SD > 6 mo) or non-responders (SD≤6 mo/PD) based on RECIST....Responders to monotherapy displayed increased expression of genes associated with a Type 1 interferon response, tissue-resident T-cells and drug targets (TIGIT, ADAR, ADORA2A, CD137, IDO1 and LAG3) (diff. p < 0.05).
DOI:
10.1200/JCO.2018.36.15_suppl.9518
